Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs

Tender description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf ofNHS England (referred to as the Commissioner), is inviting suitably qualified andexperienced providers to respond to this invitation to tender (ITT) exercise to commissionhaemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs.The haemophilia ATMP treatment hub allocation model is as follows:Lot 1 - One site to cover the NHS England population in the East of EnglandLot 2 - Two sites to cover the NHS England population in LondonLot 3 - One site to cover the NHS England population in the MidlandsLot 4 - One site to cover the NHS England population in the North East of England andYorkshireLot 5 - One site to cover the NHS England population in the North West of EnglandLot 6 - One site to cover the NHS England population in the South East of EnglandLot 7 - One site to cover the NHS England population in the South West of EnglandPlease note that providers must be located in the defined geographical catchment area(s) that they are interested in providing services to. Lot 1: Lot 1 – One site to cover the NHS England population in the East of England The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event. Lot 2: Lot 2 - Two sites to cover the NHS England population in London The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event. Lot 3: Lot 3 – One site to cover the NHS England population in the Midlands The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event. Lot 4: Lot 4 – One site to cover the NHS England population in the North East of Englan The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event. Lot 5: Lot 5 – One site to cover the NHS England population in the North West of Englan The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event. Lot 6: Lot 6 – One site to cover the NHS England population in the South East of Englan The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event. Lot 7: Lot 7 - One site to cover the NHS England population in the South West of Englan The key objectives of the Procurement are to commission Haemophilia ATMP treatment<br/>hubs for patients with haemophilia types A and B to serve the population of England, and to<br/>ensure that:<br/>• the providers of Haemophilia ATMP treatment hubs have the correct qualifications and<br/>governance arrangements in place to provide these treatments for the NHS in England, and<br/>• the Commissioner is offering services that are safe and of a high standard whilst fulfilling<br/>the Commissioner’s public duty to provide services that are cost-effective.<br/>The National Institute for Health and Care Excellence (NICE) will be assessing a number of<br/>ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected<br/>NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for<br/>patients with haemophilia types A and B. NHS England is seeking to commission eight of the<br/>18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMP<br/>treatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved by<br/>NICE with a contract duration of 8 years with the option to extend for up to a further 18<br/>months.<br/>For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,<br/>NHS England will work with the UKHCDO to develop a thorough care pathway detailing the<br/>responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to<br/>manage the care of haemophilia patients undergoing ATMP treatment.<br/>Given the significant amount of preparatory work that needs to be undertaken to deliver a<br/>gene therapy service, it is not feasible for commissioners and providers to wait until NICE has<br/>made its recommendations to commence commissioning activity.<br/>Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case that<br/>the product does not receive a positive NICE recommendation.<br/>Providers wishing to be considered for the delivery of these services will need to respond to<br/>the provider selection documentation and submit responses prior to the deadline stated in<br/>this notice.<br/>The ITT documentation including a questionnaire is available through the Atamis (Health<br/>Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and<br/>the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.<br/>There will also be an opportunity to attend a market engagement event via Microsoft Teams<br/>at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please<br/>email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and<br/>questions and responses will be made available to all bidders following the event.